Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-15
DOI
10.1186/s40425-019-0805-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.
- (2019) Roy Elias et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients
- (2019) J. Rogado et al. EUROPEAN JOURNAL OF CANCER
- Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
- (2019) V. Ellen Maher et al. JOURNAL OF CLINICAL ONCOLOGY
- Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity.
- (2019) Daniel H. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).
- (2019) Nuzzo Pier Vitale et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors.
- (2019) Rafael Morales-Barrera et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.
- (2019) Satya Das et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.
- (2019) Alexander M. M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
- (2019) Ken Masuda et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer
- (2019) Fiamma Berner et al. JAMA Oncology
- Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma
- (2019) Henry T. Quach et al. JAMA Oncology
- Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
- (2019) Elena Verzoni et al. Journal for ImmunoTherapy of Cancer
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
- (2018) Koichi Sato et al. LUNG CANCER
- Association of Immune‐Related Adverse Events with Clinical Benefit in Patients with Advanced Non‐Small‐Cell Lung Cancer Treated with Nivolumab
- (2018) Yukihiro Toi et al. ONCOLOGIST
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Mécanismes physiopathologiques des effets secondaires des immunothérapies par anticorps anti-CTLA-4, anti-PD-1 et anti-PD-L1 dans le traitement du cancer
- (2018) Tilda Passat et al. BULLETIN DU CANCER
- Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).
- (2018) Mariona Riudavets et al. JOURNAL OF CLINICAL ONCOLOGY
- Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.
- (2018) Helen Clare Dearden et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy.
- (2018) Corey Christian Foster et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-related adverse events and nivolumab outcomes in non-small cell lung cancer patients: A multi-institutional, retrospective cohort study.
- (2018) Rebecca Jane Moor et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study
- (2018) Naoto Okada et al. CLINICAL THERAPEUTICS
- Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
- (2018) Biagio Ricciuti et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
- (2018) Alice Indini et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
- (2017) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
- (2017) Shunsuke Teraoka et al. Journal of Thoracic Oncology
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- (2017) Kent W. Mouw et al. Cancer Discovery
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
- (2015) Martina Sanlorenzo et al. JAMA Dermatology
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effectiveness and Tolerability of Ipilimumab
- (2014) Thomas K. Eigentler et al. JOURNAL OF IMMUNOTHERAPY
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now